ALNYLAM PHARMACEUTICALS, INC.

Drug pipeline (4)

Asset	Stage	Revenue	Trials	Status
GIVOSIRAN SODIUM	approved	—	0	—
LUMASIRAN SODIUM	approved	—	0	—
PATISIRAN SODIUM	approved	—	0	—
VUTRISIRAN SODIUM	approved	—	1	approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (69)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT02292186	phase2	completed	2014-10-01	2017-02-22	Alnylam Pharmaceuticals	A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
NCT02452372	phase1	completed	2015-05-06	2017-09-06	Alnylam Pharmaceuticals	A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
NCT02314442	phase1	completed	2014-12-01	2015-05-01	Alnylam Pharmaceuticals	A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
NCT01814839	phase1	completed	2013-03-01	2015-04-01	Alnylam Pharmaceuticals	A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers
NCT02352493	phase1_2	completed	2015-01-01	2016-04-01	Alnylam Pharmaceuticals	A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

FDA applications (4)

Application

Type

Applicant

Products

NDA 210922

NDA

ALNYLAM PHARMACEUTICALS INC

NDA 212194

NDA

ALNYLAM PHARMACEUTICALS INC

NDA 214103

NDA

ALNYLAM PHARMACEUTICALS INC

NDA 215515

NDA

ALNYLAM PHARMACEUTICALS INC